Why Moderna Stock Rose 15.4% in July
Shares of Moderna (NASDAQ: MRNA) climbed 15.4% in July, according to data provided by S&P Global Market Intelligence, as the company advanced its coronavirus vaccine program.
Several factors helped push the stock higher throughout the month. Moderna published interim results from the phase 1 study of its vaccine candidate in The New England Journal of Medicine. Though the company released a summary in May, the most recent report included additional details.
For example, Moderna reported neutralizing antibody activity in all participants after two vaccine doses. Neutralizing antibodies have the ability to block infection, so they are seen as key in the development of a successful coronavirus vaccine. In Moderna's earlier summary, results on neutralizing antibodies were only available for eight trial participants.
Source Fool.com
